

# Alexander Reinhaller

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5843875/publications.pdf>

Version: 2024-02-01

69  
papers

3,751  
citations

394421

19  
h-index

133252

59  
g-index

71  
all docs

71  
docs citations

71  
times ranked

4594  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Pretreatment Controlling Nutritional Status Score in Ovarian Cancer: Influence on Prognosis, Surgical Outcome, and Postoperative Complication Rate. <i>Geburtshilfe Und Frauenheilkunde</i> , 2022, 82, 59-67.	1.8	3
2	Austria-based real-world data on bevacizumab in newly diagnosed epithelial ovarian cancer. <i>Wiener Klinische Wochenschrift</i> , 2022, , 1.	1.9	0
3	Topical imiquimod compared with conization to treat cervical high-grade squamous intraepithelial lesions: Multicenter, randomized controlled trial. <i>Gynecologic Oncology</i> , 2022, 165, 23-29.	1.4	16
4	Impact of frailty on the management of patients with gynecological cancer aged 80 years and older. <i>Archives of Gynecology and Obstetrics</i> , 2021, 303, 557-563.	1.7	6
5	Olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer: Japan subset from the PAOLA-1/ENGOT-ov25 trial. <i>Journal of Gynecologic Oncology</i> , 2021, 32, e82.	2.2	6
6	Risk Reclassification of Patients with Endometrial Cancer Based on Tumor Molecular Profiling: First Real World Data. <i>Journal of Personalized Medicine</i> , 2021, 11, 48.	2.5	13
7	Tumor Growth Rate Estimates Are Independently Predictive of Therapy Response and Survival in Recurrent High-Grade Serous Ovarian Cancer Patients. <i>Cancers</i> , 2021, 13, 1076.	3.7	5
8	PD-1 and PD-L1 expression on TILs in peritoneal metastases compared to ovarian tumor tissues and its associations with clinical outcome. <i>Scientific Reports</i> , 2021, 11, 6400.	3.3	14
9	The Long-Term Prognostic Significance of Circulating Tumor Cells in Ovarian Cancer—A Study of the OVCAD Consortium. <i>Cancers</i> , 2021, 13, 2613.	3.7	10
10	The systemic immune-inflammation index (SII) is an independent prognostic parameter of survival in patients with invasive vulvar cancer. <i>Journal of Gynecologic Oncology</i> , 2021, 32, e1.	2.2	14
11	miR-203 is an independent molecular predictor of prognosis and treatment outcome in ovarian cancer: a multi-institutional study. <i>Carcinogenesis</i> , 2020, 41, 442-451.	2.8	10
12	Decrease in gynecological cancer diagnoses during the COVID-19 pandemic: an Austrian perspective. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1667-1671.	2.5	33
13	Molecular Guided Treatments in Gynecologic Oncology: Analysis of a Real-World Precision Cancer Medicine Platform. <i>Oncologist</i> , 2020, 25, e1060-e1069.	3.7	4
14	Effect of Viewing Disney Movies During Chemotherapy on Self-Reported Quality of Life Among Patients With Gynecologic Cancer. <i>JAMA Network Open</i> , 2020, 3, e204568.	5.9	3
15	Epithelial ovarian cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2020, 13, 143-144.	0.5	0
16	Precision Medicine Tumor Boards: Clinical Applicability of Personalized Treatment Concepts in Ovarian Cancer. <i>Cancers</i> , 2020, 12, 548.	3.7	13
17	miR-181a overexpression predicts the poor treatment response and early progression of serous ovarian cancer patients. <i>International Journal of Cancer</i> , 2020, 147, 3560-3573.	5.1	7
18	Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 699-709.	10.7	104

#	ARTICLE	IF	CITATIONS
19	Low anterior resection syndrome (LARS) in ovarian cancer patients - A multi-centre comparative cohort study. <i>International Journal of Surgery</i> , 2020, 78, 97-102.	2.7	9
20	Prognostic value of serum creatine level in patients with vulvar cancer. <i>Scientific Reports</i> , 2019, 9, 11129.	3.3	19
21	TRUST: Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGO-ÖVAR) Tj ETQq1 1 0.784314 rgBT /O 2.5 108	1.0	108
22	Pre-operative hypoalbuminemia is associated with complication rate and overall survival in patients with vulvar cancer undergoing surgery. <i>Archives of Gynecology and Obstetrics</i> , 2019, 300, 1015-1022.	1.7	20
23	Low anterior resection syndrome (LARS) in patients with epithelial ovarian cancer after primary debulking surgery. <i>Gynecologic Oncology</i> , 2019, 154, 577-582.	1.4	8
24	Gamma-glutamyltransferase as a preoperative differential diagnostic marker in patients with adnexal mass. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2019, 239, 16-20.	1.1	2
25	Patient-derived cell line models revealed therapeutic targets and molecular mechanisms underlying disease progression of high grade serous ovarian cancer. <i>Cancer Letters</i> , 2019, 459, 1-12.	7.2	16
26	The value of pretreatment serum butyrylcholinesterase level as a novel prognostic biomarker in patients with cervical cancer treated with primary (chemo-)radiation therapy. <i>Strahlentherapie Und Onkologie</i> , 2019, 195, 430-440.	2.0	9
27	Lymph node ratio in inguinal lymphadenectomy for squamous cell vulvar cancer: Results from the AGO-CaRE-1 study. <i>Gynecologic Oncology</i> , 2019, 153, 286-291.	1.4	20
28	Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 2416-2428.	27.0	1,176
29	Factors associated with post-relapse survival in patients with recurrent cervical cancer: the value of the inflammation-based Glasgow Prognostic Score. <i>Archives of Gynecology and Obstetrics</i> , 2019, 299, 1055-1062.	1.7	19
30	Results of the extended analysis for cancer treatment (EXACT) trial: a prospective translational study evaluating individualized treatment regimens in oncology. <i>Oncotarget</i> , 2019, 10, 942-952.	1.8	11
31	A collagen-fibrin patch for the prevention of symptomatic lymphoceles after pelvic lymphadenectomy in women with gynecologic malignancies: A randomized clinical trial. <i>Gynecologic Oncology</i> , 2018, 149, 140-145.	1.4	9
32	ABO blood groups and rhesus factor expression as prognostic parameters in patients with epithelial ovarian cancer – a retrospective multi-centre study. <i>BMC Cancer</i> , 2018, 18, 447.	2.6	4
33	Predictive and Prognostic Implication of Bowel Resections During Primary Cytoreductive Surgery in Advanced Epithelial Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 1664-1671.	2.5	32
34	Risk of endometrial cancer in asymptomatic postmenopausal patients with thickened endometrium: data from the FAME-Endo study: an observational register study. <i>Archives of Gynecology and Obstetrics</i> , 2018, 298, 813-820.	1.7	13
35	AGO Austria recommendation on screening and diagnosis of Lynch syndrome (LS). <i>Archives of Gynecology and Obstetrics</i> , 2017, 296, 123-127.	1.7	8
36	Preoperative C-reactive protein serum levels as a predictive diagnostic marker in patients with adnexal masses. <i>Gynecologic Oncology</i> , 2017, 147, 690-694.	1.4	8

#	ARTICLE	IF	CITATIONS
37	Increased genitourinary fistula rate after bevacizumab in recurrent cervical cancer patients initially treated with definitive radiochemotherapy and image-guided adaptive brachytherapy. <i>Strahlentherapie Und Onkologie</i> , 2017, 193, 1056-1065.	2.0	20
38	Prognostic role of plasma fibrinogen in patients with uterine leiomyosarcoma – a multicenter study. <i>Scientific Reports</i> , 2017, 7, 14474.	3.3	14
39	Circulating tumor cells: potential markers of minimal residual disease in ovarian cancer? a study of the OVCAD consortium. <i>Oncotarget</i> , 2017, 8, 106415-106428.	1.8	42
40	The Impact of the Duration of Adjuvant Chemotherapy on Survival in Patients with Epithelial Ovarian Cancer – A Retrospective Study. <i>PLoS ONE</i> , 2017, 12, e0169272.	2.5	7
41	Development of a tool for prediction of ovarian cancer in patients with adnexal masses: Value of plasma fibrinogen. <i>PLoS ONE</i> , 2017, 12, e0182383.	2.5	12
42	Effect of Preoperative Warm-up Exercise Before Laparoscopic Gynecological Surgery: A Randomized Trial. <i>Journal of Surgical Education</i> , 2016, 73, 429-432.	2.5	11
43	Natural history of cervical intraepithelial neoplasia in pregnancy: postpartum histo-pathologic outcome and review of the literature. <i>BMC Pregnancy and Childbirth</i> , 2016, 16, 74.	2.4	33
44	The prognostic role of metformin in patients with endometrial cancer: a retrospective study. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2016, 203, 291-296.	1.1	20
45	Gamma-glutamyltransferase as novel biomarker in patients with uterine leiomyosarcoma. <i>Scientific Reports</i> , 2016, 6, 33757.	3.3	4
46	Antiangiogenic therapies in ovarian cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2016, 9, 139-143.	0.5	16
47	Prophylactic long-acting granulocyte-colony stimulating factors (G-CSF) in gynecologic malignancies: an oncologic expert statement. <i>Wiener Medizinische Wochenschrift</i> , 2015, 165, 387-394.	1.1	5
48	Progression-free survival by local investigator versus independent central review: Comparative analysis of the AGO-OVAR16 Trial. <i>Gynecologic Oncology</i> , 2015, 136, 37-42.	1.4	29
49	Pre-operative serum albumin is associated with post-operative complication rate and overall survival in patients with epithelial ovarian cancer undergoing cytoreductive surgery. <i>Gynecologic Oncology</i> , 2015, 138, 560-565.	1.4	125
50	Plasma fibrinogen levels in patients with benign and malignant ovarian tumors. <i>Gynecologic Oncology</i> , 2015, 136, 567-570.	1.4	10
51	PET/MRI in cervical cancer: Insights into tumor biology.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5597-5597.	1.6	1
52	The Prognostic Value of C-Reactive Protein Serum Levels in Patients with Uterine Leiomyosarcoma. <i>PLoS ONE</i> , 2015, 10, e0133838.	2.5	7
53	Skeletal Muscle Depletion and Markers for Cancer Cachexia Are Strong Prognostic Factors in Epithelial Ovarian Cancer. <i>PLoS ONE</i> , 2015, 10, e0140403.	2.5	92
54	Cyclin E1 (CCNE1) as independent positive prognostic factor in advanced stage serous ovarian cancer patients – A study of the OVCAD consortium. <i>European Journal of Cancer</i> , 2014, 50, 99-110.	2.8	53

#	ARTICLE	IF	CITATIONS
55	Independent review of AGO-OVAR 12, a GCIG/ENGOT-Intergroup phase III trial of nintedanib (N) in first-line therapy for ovarian cancer (OC).. Journal of Clinical Oncology, 2014, 32, 5556-5556.	1.6	2
56	Cervical Adenocarcinoma in Situ: Update and Management. Current Obstetrics and Gynecology Reports, 2013, 2, 86-93.	0.8	6
57	The role of gamma-glutamyltransferase in malignant transformation and prognosis of ovarian cancer.. Journal of Clinical Oncology, 2013, 31, e16524-e16524.	1.6	0
58	Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or carboplatin plus pegylated doxorubicin (PLDC): A randomized phase III trial of the NOGGO-AGO-Germany-AGO Austria and GEICO-GCIG intergroup study (HECTOR).. Journal of Clinical Oncology, 2012, 30, 5031-5031.	1.6	4
59	A matched pair analysis of intra- and postoperative catumaxomab in patients with ovarian cancer from a multicenter, single-arm phase II trial versus a consecutive single-center collective of ovarian cancer patients without immunotherapy.. Journal of Clinical Oncology, 2012, 30, 5080-5080.	1.6	5
60	Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: A GCIG and EORTC-GCG study.. Journal of Clinical Oncology, 2012, 30, LBA5000-LBA5000.	1.6	7
61	Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: A GCIG and EORTC-GCG study.. Journal of Clinical Oncology, 2012, 30, LBA5000-LBA5000.	1.6	12
62	Nomogram prediction for overall survival of patients diagnosed with cervical cancer.. Journal of Clinical Oncology, 2012, 30, 5111-5111.	1.6	0
63	Clinical outcome of protocol based image (MRI) guided adaptive brachytherapy combined with 3D conformal radiotherapy with or without chemotherapy in patients with locally advanced cervical cancer. Radiotherapy and Oncology, 2011, 100, 116-123.	0.6	649
64	The Inflammation-Based Glasgow Prognostic Score Predicts Survival in Patients With Cervical Cancer. International Journal of Gynecological Cancer, 2010, 20, 1052-1057.	2.5	44
65	Assessment of a six gene panel for the molecular detection of circulating tumor cells in the blood of female cancer patients. BMC Cancer, 2010, 10, 666.	2.6	96
66	3D MRI-based brachytherapy for cervical cancer. Expert Review of Obstetrics and Gynecology, 2008, 3, 351-358.	0.4	2
67	Clinical impact of MRI assisted dose volume adaptation and dose escalation in brachytherapy of locally advanced cervix cancer. Radiotherapy and Oncology, 2007, 83, 148-155.	0.6	475
68	C-reactive protein is a prognostic parameter in patients with cervical cancer. Gynecologic Oncology, 2007, 107, 114-117.	1.4	72
69	Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer. Gynecologic Oncology, 2006, 103, 512-517.	1.4	124